Four BC Platforms–supported abstracts were presented at the 2025 ASCO Annual Meeting, showcasing how Real-World Data (RWD), radiomics, and secure data environments (SDEs) are transforming lung cancer research. These studies highlight advances in cohort design, progression-free survival modeling, and the integration of imaging and clinical data to accelerate precision oncology.
The four abstracts published in the Journal of Clinical Oncology are available in our resource center:
“Relevance and Specificity of the French CIAN LUNG Cohort for Clinical Research Analyses in Lung Cancer Using Real-World Data”
“Dynamic Longitudinal Patient Cohorts Using Hospital Electronic Medical Record (EMR) Data via Secure Data Environment (SDE) Technology to Generate Real-World Evidence (RWE)”
“Impact of Radiomic Features on Prediction of Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Stage IV”
“Methodology for Estimation of Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Using Real-World Data from a French Cohort”
Relevance and specificity of the CIAN Lung cohort for clinical research analyses in cancer
The CIAN LUNG cohort is a multicentric initiative using clinical, imaging, and biomarker data to generate Real-World Evidence and advance lung cancer research.
Dynamic longitudinal patient cohorts using hospital EMR data to generate RWE
Secure Data Environment technology enables dynamic patient cohorts that continuously update real-world evidence from EMR data across global hospital networks.
Methodology for estimation of progression-free survival in patients with NSCLC
A new methodology from the CIAN LUNG cohort demonstrates how real-world data can be used to estimate progression-free survival in non-small cell lung cancer.
Relevance and specificity of the CIAN Lung cohort for clinical research analyses in cancer
The CIAN LUNG cohort is a multicentric initiative using clinical, imaging, and biomarker data to generate Real-World Evidence and advance lung cancer research.
Methodology for estimation of progression-free survival in patients with NSCLC
A new methodology from the CIAN LUNG cohort demonstrates how real-world data can be used to estimate progression-free survival in non-small cell lung cancer.
